Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer.
Concurrent vinablastine-based radiochemotherapy was evaluated in 84 bladder-cancer patients. It was effective in more than half: tumour-specific survival (51% 9-year), local control rate (55% 9-year). The drawback was the impaired function of the bladder (9-year prevalence SOMA G3-4 symptoms: 66%), indicating the need for treatment aimed at reducing chronic morbidity.
Kragelj
Borut
B
Department of Radiation Therapy, Institute of Oncology, SI-1000 Ljubljana, Slovenia. bjragelj@onko-i.si
Zaletel-Kragelj
Lijana
L
Sedmak
Boris
B
Cufer
Tanja
T
Cervek
Jozica
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine